StockNews.AI
ATRC
StockNews.AI
209 days

AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results

1. AtriCure will release Q4 and FY 2024 financial results on February 12, 2025. 2. Audio webcast to discuss financial results is scheduled for the same date. 3. AtriCure's devices are key for treating Afib, which affects 59 million globally. 4. FDA-approved products include the Isolator® Synergy™ Ablation System. 5. AtriCure's systems are leading solutions in LAA management and pain relief.

Earnings
+1.1%Current Return
VS
+0.76%S&P 500
$39.6301/22 08:14 AM EDTEvent Start
$40.06501/23 03:03 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results may show strong demand for Afib treatments, likely boosting ATRC's stock. Similar instances before earnings have showcased stock price increases based on anticipated positive performance.

How important is it?

The earnings announcement and the growing market for Afib treatments provide substantial insight into ATRC's growth potential.

Why Short Term?

The release of financial results will have immediate effects on stock valuation. Recent earnings calls have often resulted in quick market reactions.

Related Companies

AFIBMAKOISRG
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.

Related News